Vanda Pharmaceuticals Inc. (VNDA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-08

Vanda Pharmaceuticals Inc. (VNDA) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-08. 3 Form 8-K material event filings were reported by VNDA in the last 90 days. InsiderAlpha tracks every VNDA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Vanda Pharmaceuticals Inc. (VNDA)

SEC CIK	0001347178

90-Day SEC Filing Activity

Form 4 filings (90d)	9
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-06-08

Recent VNDA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-04	McGuire Daniel Patrick	SVP, GC and Secretary	A — Grant or award	80.0K	$0.00	—	SEC
2026-06-04	Mitchell Stephen Ray	Insider	A — Grant or award	41.6K	$0.00	—	SEC
2026-06-04	Duncan Charles Cliff	Insider	A — Grant or award	41.6K	$0.00	—	SEC
2026-06-04	Chrousos Phaedra	Insider	A — Grant or award	41.6K	$0.00	—	SEC
2026-06-04	Honore Tage	Insider	A — Grant or award	41.6K	$0.00	—	SEC
2026-06-04	Ward Anne Sempowski	Insider	A — Grant or award	41.6K	$0.00	—	SEC
2026-06-04	DUGAN RICHARD W	Insider	A — Grant or award	41.6K	$0.00	—	SEC
2026-05-18	Mitchell Stephen Ray	Insider	G — Bona-fide gift	25.8K	$0.00	—	SEC
2026-04-22	Duncan Charles Cliff	Insider	A — Grant or award	57.1K	$0.00	—	SEC
2026-03-02	Polymeropoulos Mihael Hristos	President and CEO	S — Open-market sale	156.2K	$8.17	$1.28M	SEC
2026-03-02	Moran Kevin Patrick	SVP, CFO & Treasurer	S — Open-market sale	42.4K	$8.27	$351K	SEC
2026-03-02	Wijkstrom Joakim	SVP, Chief Marketing Officer	S — Open-market sale	30.8K	$8.27	$255K	SEC
2026-03-02	Birznieks Gunther	SVP, Business Development	S — Open-market sale	42.4K	$8.27	$351K	SEC
2026-03-02	Williams Timothy	SVP & General Counsel	S — Open-market sale	42.4K	$8.27	$351K	SEC
2026-02-23	Honore Tage	Insider	S — Open-market sale	30.0K	$8.03	$241K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Vanda Pharmaceuticals Inc. (VNDA). Updated in real time as new filings are submitted to the SEC.

Most-Active VNDA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Mitchell Stephen Ray	2	—
Duncan Charles Cliff	2	—
Ward Anne Sempowski	1	—
Chrousos Phaedra	1	—
McGuire Daniel Patrick	1	—

Recent VNDA Form 8-K Material Events

2026-06-05 — Item 5.07 [SEC]
2026-05-06 — Item 2.02, 9.01 [SEC]
2026-04-22 — Item 5.02, 9.01 · Leadership · neutral [SEC]
Vanda Pharmaceuticals expanded its Board of Directors from six to seven members and appointed Charles C. Duncan, Ph.D., as a Class II director effective immediately. Dr. Duncan will receive standard outside director compensation including an initial restricted stock unit award va
2026-04-02 — Item 5.02 · Leadership · neutral [SEC]
Timothy Williams, Senior Vice President, General Counsel and Secretary of Vanda Pharmaceuticals, resigned effective April 10, 2026, to pursue other endeavors. This is a departure of a senior legal officer but not a C-suite executive like CEO or CFO.
2026-03-10 — Item 7.01 · Clinical · positive [SEC]
Vanda Pharmaceuticals' CEO announced on Fox Business that the company's recently FDA-approved drug NEREUS (for motion-induced vomiting prevention) will be available to patients in the next couple of months through a direct-to-consumer channel called NEREUSRX. This represents the

Recent Insider Filings

2026-06-08 — McGuire Daniel Patrick (SVP, GC and Secretary)
2026-06-08 — Chrousos Phaedra (Insider)
2026-06-08 — Duncan Charles Cliff (Insider)
2026-06-08 — DUGAN RICHARD W (Insider)
2026-06-08 — Ward Anne Sempowski (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in VNDA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

VNDA Insider Trading — FAQ

What is the latest insider trade for VNDA?: Vanda Pharmaceuticals Inc. (VNDA) had 9 insider filings in the last 90 days, with the most recent on 2026-06-08. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying VNDA stock?: 0 insider purchases of VNDA were filed in the last 90 days.
How many insiders are selling VNDA stock?: 0 insider sales of VNDA were filed in the last 90 days.
Where can I see VNDA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every VNDA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live VNDA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.